Drug Trial Radar · NCT06972732
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Jun 11, 2025
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Boryung Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.
Conditions
- Type 2 Diabetes
Interventions
MetforminDrug
The dosage and dose frequency are maintained as they were before the screening.
Dapagliflozin/PioglitazoneDrug
Dapagliflozin 10mg/Pioglitazone 30mg QD
Dapagliflozin/SitagliptinDrug
Dapagliflozin 10mg/Sitagliptin 100mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)Time frame: From baseline to end of treatment at 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, Seocho District, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.